Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. / Wewer Albrechtsen, Nicolai J; Hornburg, Daniel; Albrechtsen, Reidar; Svendsen, Berit; Toräng, Signe; Jepsen, Sara L; Kuhre, Rune E; Hansen, Marie; Janus, Charlotte; Floyd, Andrea; Lund, Asger; Lauritsen, Tina Vilsbøll; Knop, Filip K; Vestergaard, Henrik; Deacon, Carolyn F; Meissner, Felix; Mann, Matthias; Holst, Jens J; Hartmann, Bolette.

In: EBioMedicine, Vol. 7, 05.2016, p. 112-120.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Wewer Albrechtsen, NJ, Hornburg, D, Albrechtsen, R, Svendsen, B, Toräng, S, Jepsen, SL, Kuhre, RE, Hansen, M, Janus, C, Floyd, A, Lund, A, Lauritsen, TV, Knop, FK, Vestergaard, H, Deacon, CF, Meissner, F, Mann, M, Holst, JJ & Hartmann, B 2016, 'Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma', EBioMedicine, vol. 7, pp. 112-120. https://doi.org/10.1016/j.ebiom.2016.03.034

APA

Wewer Albrechtsen, N. J., Hornburg, D., Albrechtsen, R., Svendsen, B., Toräng, S., Jepsen, S. L., ... Hartmann, B. (2016). Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. EBioMedicine, 7, 112-120. https://doi.org/10.1016/j.ebiom.2016.03.034

Vancouver

Wewer Albrechtsen NJ, Hornburg D, Albrechtsen R, Svendsen B, Toräng S, Jepsen SL et al. Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. EBioMedicine. 2016 May;7:112-120. https://doi.org/10.1016/j.ebiom.2016.03.034

Author

Wewer Albrechtsen, Nicolai J ; Hornburg, Daniel ; Albrechtsen, Reidar ; Svendsen, Berit ; Toräng, Signe ; Jepsen, Sara L ; Kuhre, Rune E ; Hansen, Marie ; Janus, Charlotte ; Floyd, Andrea ; Lund, Asger ; Lauritsen, Tina Vilsbøll ; Knop, Filip K ; Vestergaard, Henrik ; Deacon, Carolyn F ; Meissner, Felix ; Mann, Matthias ; Holst, Jens J ; Hartmann, Bolette. / Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. In: EBioMedicine. 2016 ; Vol. 7. pp. 112-120.

Bibtex

@article{8f4d7938309d44a9919acce01f2cb115,
title = "Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma",
abstract = "Low-abundance regulatory peptides, including metabolically important gut hormones, have shown promising therapeutic potential. Here, we present a streamlined mass spectrometry-based platform for identifying and characterizing low-abundance regulatory peptides in humans. We demonstrate the clinical applicability of this platform by studying a hitherto neglected glucose- and appetite-regulating gut hormone, namely, oxyntomodulin. Our results show that the secretion of oxyntomodulin in patients with type 2 diabetes is significantly impaired, and that its level is increased by more than 10-fold after gastric bypass surgery. Furthermore, we report that oxyntomodulin is co-distributed and co-secreted with the insulin-stimulating and appetite-regulating gut hormone glucagon-like peptide-1 (GLP-1), is inactivated by the same protease (dipeptidyl peptidase-4) as GLP-1 and acts through its receptor. Thus, oxyntomodulin may participate with GLP-1 in the regulation of glucose metabolism and appetite in humans. In conclusion, this mass spectrometry-based platform is a powerful resource for identifying and characterizing metabolically active low-abundance peptides.",
author = "{Wewer Albrechtsen}, {Nicolai J} and Daniel Hornburg and Reidar Albrechtsen and Berit Svendsen and Signe Tor{\"a}ng and Jepsen, {Sara L} and Kuhre, {Rune E} and Marie Hansen and Charlotte Janus and Andrea Floyd and Asger Lund and Lauritsen, {Tina Vilsb{\o}ll} and Knop, {Filip K} and Henrik Vestergaard and Deacon, {Carolyn F} and Felix Meissner and Matthias Mann and Holst, {Jens J} and Bolette Hartmann",
note = "Copyright {\circledC} 2016 The Authors. Published by Elsevier B.V. All rights reserved.",
year = "2016",
month = "5",
doi = "10.1016/j.ebiom.2016.03.034",
language = "English",
volume = "7",
pages = "112--120",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma

AU - Wewer Albrechtsen, Nicolai J

AU - Hornburg, Daniel

AU - Albrechtsen, Reidar

AU - Svendsen, Berit

AU - Toräng, Signe

AU - Jepsen, Sara L

AU - Kuhre, Rune E

AU - Hansen, Marie

AU - Janus, Charlotte

AU - Floyd, Andrea

AU - Lund, Asger

AU - Lauritsen, Tina Vilsbøll

AU - Knop, Filip K

AU - Vestergaard, Henrik

AU - Deacon, Carolyn F

AU - Meissner, Felix

AU - Mann, Matthias

AU - Holst, Jens J

AU - Hartmann, Bolette

N1 - Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

PY - 2016/5

Y1 - 2016/5

N2 - Low-abundance regulatory peptides, including metabolically important gut hormones, have shown promising therapeutic potential. Here, we present a streamlined mass spectrometry-based platform for identifying and characterizing low-abundance regulatory peptides in humans. We demonstrate the clinical applicability of this platform by studying a hitherto neglected glucose- and appetite-regulating gut hormone, namely, oxyntomodulin. Our results show that the secretion of oxyntomodulin in patients with type 2 diabetes is significantly impaired, and that its level is increased by more than 10-fold after gastric bypass surgery. Furthermore, we report that oxyntomodulin is co-distributed and co-secreted with the insulin-stimulating and appetite-regulating gut hormone glucagon-like peptide-1 (GLP-1), is inactivated by the same protease (dipeptidyl peptidase-4) as GLP-1 and acts through its receptor. Thus, oxyntomodulin may participate with GLP-1 in the regulation of glucose metabolism and appetite in humans. In conclusion, this mass spectrometry-based platform is a powerful resource for identifying and characterizing metabolically active low-abundance peptides.

AB - Low-abundance regulatory peptides, including metabolically important gut hormones, have shown promising therapeutic potential. Here, we present a streamlined mass spectrometry-based platform for identifying and characterizing low-abundance regulatory peptides in humans. We demonstrate the clinical applicability of this platform by studying a hitherto neglected glucose- and appetite-regulating gut hormone, namely, oxyntomodulin. Our results show that the secretion of oxyntomodulin in patients with type 2 diabetes is significantly impaired, and that its level is increased by more than 10-fold after gastric bypass surgery. Furthermore, we report that oxyntomodulin is co-distributed and co-secreted with the insulin-stimulating and appetite-regulating gut hormone glucagon-like peptide-1 (GLP-1), is inactivated by the same protease (dipeptidyl peptidase-4) as GLP-1 and acts through its receptor. Thus, oxyntomodulin may participate with GLP-1 in the regulation of glucose metabolism and appetite in humans. In conclusion, this mass spectrometry-based platform is a powerful resource for identifying and characterizing metabolically active low-abundance peptides.

U2 - 10.1016/j.ebiom.2016.03.034

DO - 10.1016/j.ebiom.2016.03.034

M3 - Journal article

C2 - 27322465

VL - 7

SP - 112

EP - 120

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

ER -

ID: 162643439